Form 4: STERIS plc Executive Julia Madsen Reports Significant Equity Awards in Latest SEC Filing

Julia Madsen, Senior VP and General Manager of Life Sciences at STERIS plc, reported the acquisition of 1,998 ordinary shares and 7,100 employee stock options on June 3, 2025, as part of her compensation.

Summary

• Julia Madsen, Senior VP and GM, Life Sciences at STERIS plc (STE), reported changes in her beneficial ownership of company securities.
• On June 3, 2025, Ms. Madsen acquired 1,998 ordinary shares at a price of $0, likely as part of an equity grant or award.
• Following this transaction, Ms. Madsen beneficially owns a total of 10,956 ordinary shares.
• Of the ordinary shares, 4,689 are restricted and subject to a vesting schedule, with portions lapsing on various dates between June 4, 2025, and June 5, 2028.
• Ms. Madsen also acquired 7,100 employee stock options on June 3, 2025, at an exercise price of $267.66 per share, also at an acquisition price of $0.
• These employee stock options have an expiration date of June 3, 2035.
• The 7,100 employee stock options vest in four equal annual installments of 1,775 options each, beginning on June 3, 2026, and continuing through June 4, 2029.

Sentiment

Score: 7

Explanation: The filing indicates routine equity compensation grants to a senior executive, which aligns management's interests with shareholders and is generally viewed positively, though it's not a significant market-moving event or an indicator of operational performance.

Positives

• The acquisition of ordinary shares and employee stock options by a senior executive aligns management's interests with those of shareholders, promoting long-term value creation.
• Equity compensation is a standard practice that incentivizes executives to contribute to the company's performance and growth.

Future Outlook

This Form 4 filing primarily reports past transactions and does not contain explicit forward-looking statements or guidance regarding the company's future performance or strategic direction. However, the vesting schedules for the equity awards extend into future years, indicating a long-term incentive structure for the executive.

Management Comments

• The filing itself, signed by an authorized representative under Power of Attorney, serves as a formal disclosure by management regarding executive equity ownership changes.

Industry Context

Form 4 filings are routine disclosures in the U.S. public markets, mandated by the SEC for insiders to report changes in their beneficial ownership. The granting of equity awards, such as restricted shares and stock options, is a common component of executive compensation packages across various industries, including the life sciences and healthcare sectors where STERIS plc operates. This practice aims to align executive incentives with shareholder interests.

Stakeholder Impact

• Shareholders: The equity grants align the interests of a key executive with those of shareholders, potentially fostering long-term value creation.
• Employees: While not directly impacting all employees, executive compensation practices can influence overall company culture and compensation strategies.

Next Steps

• Continued vesting of 4,689 restricted ordinary shares on various dates through June 5, 2028.
• Continued vesting of 7,100 employee stock options in annual installments through June 4, 2029.

Key Dates

Keywords

STERIS plc, STE, Form 4, Insider Transaction, Equity Compensation, Stock Options, Restricted Stock, Julia Madsen, Executive Compensation, Beneficial Ownership